Isomorphic Labs, a London-based company focused on AI-driven drug discovery, has raised $600 million in its first external funding round. The round was led by Thrive Capital, with participation from GV and Alphabet Inc. The funds will be used to advance Isomorphic's AI drug design engine and to further develop its therapeutic programs in oncology and immunology. The company, founded by Sir Demis Hassabis, has been working on AI models to design drugs and predict molecular structures, including the development of AlphaFold 3 in collaboration with Google DeepMind. Isomorphic Labs has also established partnerships with Eli Lilly and Novartis to develop small molecule programs in these areas.